Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

PAH

This page shows the latest PAH news and features for those working in and with pharma, biotech and healthcare.

Janssen’s single tablet combination shows promise in phase 3 PAH study

Janssen’s single tablet combination shows promise in phase 3 PAH study

PAH is a rare, progressive and life-threatening blood vessel disorder characterised by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation, resulting in a significant ... An estimated 500 to 1, 000 new

Latest news

More from news
Approximately 5 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • My journey advancing the science in pulmonary hypertension My journey advancing the science in pulmonary hypertension

    Most recently at Janssen, we have collaborated with patients and healthcare professionals to create a first-of-its-kind pulmonary arterial hypertension (PAH) Patient Charter, designed to set the baseline for ... holistic PAH care.

  • Understanding the ‘real world’ starts and ends with the patient Understanding the ‘real world’ starts and ends with the patient

    For regularly misunderstood rare disease patients, such as those with PAH, this information is critical for developing medicines that may not only improve their prognosis but also their everyday lives. ... PAH treatment strategies or interventions, an

  • Six degrees of participation Six degrees of participation

    For example, our recent work to design a patient and carer mobile application for PAH has benefited from ongoing collaboration with clinicians, patient advocacy groups and leading tertiary centres across the

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck &Co grew cardiovascular revenues by 130%, while GSK enjoyed a 214% uplift, mainly due to its PAH treatment Volibris.

  • Pharma deals in September 2015 Pharma deals in September 2015

    In an attempt to be hunter rather than hunted, and to diversify its portfolio from just PAH (pulmonary arterial hypertension), Actelion has acknowledged it is holding “preliminary discussions with ZS Pharma”. ... complement Actelion's PAH portfolio.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... strong long-term growth potential to achieve leading positions in

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...

Quick links